trump glp 1 announcement Novo Nordisk, Lilly strike deal with to slash weight-loss drug prices President Trump announced the popular

National Taiwan University researchers highlight the benefits of GLP-1 receptor agonists (GLP-1 RAs) in reducing mortality and severe cardiovascular and renal outcomes for diabetic patients with acute kidney disease (AKD)

Explore BPS Biosciences solutions for GLP-1R research in diabetes

Learn how weight loss drug coverage is changing for Medicare GLP-1 prescriptions in 2026 and how Absolute Best Insurance can help review options.

In our newly released white paper, From Managing Illness to Building Health, we outline why fragmented, condition-specific approaches are no longer aligned with clinical science or financial outcomes and what a more integrated, prevention-focused model looks like in practice

Glucagon-like peptide-1 (GLP-1) is a hormone involved in glucose homeostasis and satiety regulation

The global GLP-1 agonists market is expected to reach USD 170.75 billion in 2033 from USD 64.42 billion in 2025 at a CAGR of 13.0% during the forecast period